Stockscreener 앱 받기
0.9318
1.86%
-0.0177
시간 외 거래:
.98
0.0482
+5.17%
전일 마감가:
$0.9495
열려 있는:
$0.96
하루 거래량:
1.66M
Relative Volume:
1.38
시가총액:
$111.21M
수익:
-
순이익/손실:
$-25.91M
주가수익비율:
-3.702
EPS:
-0.2517
순현금흐름:
$-22.73M
1주 성능:
+16.46%
1개월 성능:
+9.62%
6개월 성능:
-7.74%
1년 성능:
+39.47%
1일 변동 폭
$0.9155
$0.9682
1주일 범위
$0.7786
$0.9682
52주 변동 폭
$0.5614
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
명칭
Oncolytics Biotech Inc
전화
(403) 670-7377
주소
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.9318 | 101.47M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-13 | 개시 | Lake Street | Buy |
| 2022-10-06 | 개시 | Maxim Group | Buy |
| 2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
JonesTrading Maintains Oncolytics Biotech(ONCY.US) With Hold Rating - Moomoo
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights - ACCESS Newswire
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
ONCY: Promising GI cancer data and new patent strategies position pelareorep for major milestones - TradingView
ONCY: Pivotal data for a novel IV oncolytic virus in GI cancers expected by year-end - TradingView
Oncolytics schedules FDA meeting on anal cancer drug pathway - Investing.com
Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention - Yahoo Finance
Oncolytics Biotech (NASDAQ: ONCY) director Stephen Glover files initial Form 3 - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) grants director 30,000 options - Stock Titan
VersaFi ferme les marchés - Barchart.com
ONCOLYTICS BIOTECH (ONCY) CMO awarded 260,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech (ONCY) COO discloses 500,000-share stock option holding - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) grants director Rigby 30,000 options - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) director granted options on 30,000 shares at $1.06 - Stock Titan
ONCOLYTICS (ONCY) CFO receives 260,000 stock options at $1.06 exercise price - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) CBO receives 260,000 stock options at $1.06 exercise price - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) CEO awarded 755,000 options at $1.06 strike - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options grant at $1.06 - Stock Titan
ONCOLYTICS (NASDAQ: ONCY) director awarded stock options on 30,000 shares - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) CTO awarded 260,000 stock options at $1.06 strike - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives stock options on 30,000 shares - Stock Titan
145,000 stock options granted to Oncolytics (ONCY) COO McAdory - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) director receives 96,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech Strengthens Leadership with New COO, Director - The Globe and Mail
Oncolytics Biotech Appoints Steve Glover to Board and Promotes John McAdory to COO - geneonline.com
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics appoints Glover to board, promotes McAdory to COO - Investing.com UK
Signs of Abundant Global Supplies Undercut Sugar Prices - Barchart.com
Wall Street May Still Be Looking at the Old Oncolytics Story - Barchart.com
Best Compounded Tirzepatide Online Provider (2026) Report Published by Kinross Research - Barchart.com
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer - The IFP
Oncolytics appoints Glover to board, promotes McAdory to COO By Investing.com - Investing.com Canada
Oncolytics (ONCY) Reports Promising Preclinical Study Results - GuruFocus
Oncolytics Biotech Reports Positive Preclinical Data for Pelareorep and RAS Inhibitor Combo in Solid Tumors - Minichart
Oncolytics Biotech (Nasdaq: ONCY) posts early pelareorep RAS-combo data - Stock Titan
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches - marketscreener.com
Oncolytics Biotech® Announces Positive Initial Preclinical - GlobeNewswire
How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks? - Barchart.com
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story - ACCESS Newswire
ONCY Stock Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
ONCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
Analyst Jared Kelly Highlights Potential Opportunities for Oncolytics Biotech in Oncology Sector - geneonline.com
H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy By Investing.com - Investing.com Australia
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oncolytics Biotech Inc 주식 (ONCY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Mar 12 '26 |
Buy |
0.96 |
5,050 |
4,848 |
114,050 |
| Kelly Jared | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.84 |
29,500 |
24,839 |
109,000 |
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
2.60%
0.94%
자본화:
|
볼륨(24시간):